Cargando…

Hyperprogression After Immunotherapy for Primary Small Cell Neuroendocrine Carcinoma of the Ureter: A Case Report

BACKGROUND: Primary small cell neuroendocrine carcinoma (SCNEC) in the ureter is extremely rare and has been sporadically reported in case reports. Its incidence, diagnosis, treatment, and outcomes have not yet been thoroughly understood. Here we present a patient with advanced SCNEC in the ureter w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qing, Defeng, Peng, Luxing, Cen, Feng, Huang, Xinjun, Wei, Qiang, Lu, Heming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8416087/ https://www.ncbi.nlm.nih.gov/pubmed/34485132 http://dx.doi.org/10.3389/fonc.2021.696422

Ejemplares similares

Hyperprogression after immunotherapy
por: Abbas, Waseem, et al.
Publicado: (2019)

Hyperprogressive disease after avelumab maintenance therapy in a patient with advanced ureter cancer: A case report
por: Ogasawara, Keita, et al.
Publicado: (2022)

Collision Carcinoma Involving Small Cell Neuroendocrine Carcinoma and Squamous Cell Carcinoma of the Ureter: A Case Report and Review of the Literature
por: Xu, Sheng, et al.
Publicado: (2021)

Primary small cell carcinoma of the ureter with hydronephrosis: A case report
por: Sato, Ryuta, et al.
Publicado: (2019)

Hyperprogressive Disease After Immunotherapy: A Case Report of Pulmonary Enteric Adenocarcinoma
por: Hu, Chun-Hong, et al.
Publicado: (2022)

Hyperprogression under Immunotherapy
por: Frelaut, Maxime, et al.
Publicado: (2019)

Cardiac infarction caused by PD-1 inhibitor during small cell neuroendocrine carcinoma of the ureter treatment: A case report
por: Li, Xiaoying, et al.
Publicado: (2023)

Imaging manifestations of small cell neuroendocrine carcinoma of the ureter
por: Chen, Guiwu, et al.
Publicado: (2023)

Hyperprogression After Immune-Checkpoint Inhibitor Treatment: Characteristics and Hypotheses
por: Zang, Hongjing, et al.
Publicado: (2020)

Dosimetric study of a respiratory gating technique based on four-dimensional computed tomography in non-small-cell lung cancer
por: Lin, Hui, et al.
Publicado: (2014)

Hyperprogression after immunotherapy in patients with malignant tumors of digestive system
por: Ji, Zhi, et al.
Publicado: (2019)

Metastatic serous endometrial carcinoma to the ureter
por: Sahl, Jessa W., et al.
Publicado: (2021)

Hyperprogression after Immunotherapy: Nivolumab. Analysis of Imaging Findings Associated with Hyperprogression and Tumor Growth Kinetics
por: Singla, Rishu, et al.
Publicado: (2021)

Unravelling the underpinnings of hyperprogression and immunotherapy: back to the bench
por: Subbiah, Vivek, et al.
Publicado: (2022)

Is hyperprogressive disease a specific phenomenom of immunotherapy?
por: Brambilla, Marta, et al.
Publicado: (2020)

Hyperprogression and Immunotherapy: Fact, Fiction, or Alternative Fact?
por: Adashek, Jacob J., et al.
Publicado: (2020)

Hyperprogressive disease in non-small cell lung cancer treated with immune checkpoint inhibitor therapy, fact or myth?
por: Britt, Alec S., et al.
Publicado: (2022)

Small cell neuroendocrine carcinoma of the ureter: A case report and literature review
por: PING, JIANG HAI, et al.
Publicado: (2014)

Redefine Hyperprogressive Disease During Treatment With Immune-Checkpoint Inhibitors in Patients With Gastrointestinal Cancer
por: Wang, Zhenghang, et al.
Publicado: (2021)

Primary large-cell neuroendocrine carcinoma of the upper ureter: A case report
por: Choi, Jae Hwi, et al.
Publicado: (2019)

Hyperprogression: A novel response pattern under immunotherapy
por: Han, Xue‐jiao, et al.
Publicado: (2020)

Hyperprogression in PDL1 Expressive, Recurrent Gastroesophageal-junction Adenocarcinoma After Pembrolizumab
por: Sama, Shashank, et al.
Publicado: (2019)

Genomic alterations associated with pseudoprogression and hyperprogressive disease during anti-PD1 treatment for advanced non-small-cell lung cancer
por: Zhou, Rui, et al.
Publicado: (2023)

Case report: Strategies for improving outcomes in patients with primary ovarian small-cell neuroendocrine carcinoma
por: Li, YingYing, et al.
Publicado: (2022)

Primary non-Hodgkin lymphoma of kidney and ureter mimicking an upper tract urothelial carcinoma: A case report
por: Wallad, Caesar Khairul, et al.
Publicado: (2019)

Hyperprogression of Liver Metastasis With Neoadjuvant Immunotherapy for Soft Tissue Sarcoma
por: Chan, Abigail S, et al.
Publicado: (2020)

Hyperprogressive Disease After Combined Anti-PD-L1 and Anti-CTLA-4 Immunotherapy for MSI-H/dMMR Gastric Cancer: A Case Report
por: Varnier, Romain, et al.
Publicado: (2021)

Hyperprogression under immunotherapy: a new form of immunotherapy response?—a narrative literature review
por: Lin, Miaozhen, et al.
Publicado: (2021)

Multicentric small cell neuroendocrine neoplasm of the renal pelvis and ureter with concomitant focal high-grade urothelial carcinoma of the ureter: A case report
por: Banerji, John S., et al.
Publicado: (2008)

Metastatic melanoma to the proximal ureter
por: DeSanto, Matthew, et al.
Publicado: (2023)

Metastatic Renal Cell Carcinoma to the Contralateral Ureter: A Rare Phenomenon
por: Dixon, Ashley, et al.
Publicado: (2015)

An unusual case of renal cell carcinoma with tumor thrombosis of the proximal ureter
por: Bowman, Max, et al.
Publicado: (2018)

Clear cell variant, urothelial carcinoma of ureter: A rare entity
por: Mahajan, Anuj, et al.
Publicado: (2020)

PET/CT radiomics for prediction of hyperprogression in metastatic melanoma patients treated with immune checkpoint inhibitors
por: Gabryś, H. S., et al.
Publicado: (2022)

Extremely high infiltration of CD8(+)PD-L1(+) cells detected in a stage III non-small cell lung cancer patient exhibiting hyperprogression during anti-PD-L1 immunotherapy after chemoradiation: A case report
por: Wu, Changshun, et al.
Publicado: (2022)

Comparative Study of Pulmonary Combined Large-Cell Neuroendocrine Carcinoma and Combined Small-Cell Carcinoma in Surgically Resected High-Grade Neuroendocrine Tumors of the Lung
por: Wang, Yanan, et al.
Publicado: (2021)

Hyperprogressive disease in patients suffering from solid malignancies treated by immune checkpoint inhibitors: A systematic review and meta-analysis
por: Zhao, Zijun, et al.
Publicado: (2022)

Ifosfamide-Induced Malignancy of Ureter and Bladder
por: Sannu, Aparna, et al.
Publicado: (2017)

Hyperprogressive Disease In Cervical Small Cell Carcinoma Treated By Immune Checkpoint Inhibitor
por: Xu, Zihan, et al.
Publicado: (2019)

Hyperprogression: A Unique Phenomenon of Progression of Existing Tumor Secondary to Immunotherapy
por: Mandal, Shobha, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_f7kja6d3vh1dsh3k3nkm5asg40